• Proteomic Shifts in Lung Adenocarcinoma after HSP90 Inhibiti

  2026-05-22

  This study uses proteomic profiling to reveal how HSP90 inhibition alters signaling and metabolic pathways in lung adenocarcinoma cells. Findings highlight new candidate biomarkers and clarify the molecular consequences of targeting chaperone networks, informing further research on apoptosis and cancer therapy resistance.

• Metformin-Induced EDH in Colitis: Mechanisms and Implication

  2026-05-22

  This study reveals that metformin induces vasorelaxation in mesenteric arterioles via endothelium-dependent hyperpolarization (EDH), a mechanism that remains robust even during ulcerative colitis. By delineating calcium signaling pathways and demonstrating metformin's ability to restore impaired acetylcholine responses, the work provides actionable insights for cardiovascular and inflammatory research.

• Cholesterol Impedes Intracellular Trafficking of Lipid Nanop

  2026-05-21

  A recent study demonstrates that elevated cholesterol content in lipid nanoparticle (LNP) formulations hinders the intracellular trafficking and delivery efficiency of nucleic acid cargo. By dissecting the mechanistic impact of LNP composition on endosomal escape, the research provides actionable insights for optimizing LNP design in nucleic acid delivery applications.

• Ertugliflozin Reduces Tau Hyperphosphorylation in Alzheimer’

  2026-05-21

  This study demonstrates that the SGLT2 inhibitor ertugliflozin attenuates cognitive deficits and decreases tau hyperphosphorylation in a rat model of Alzheimer’s disease by restoring brain insulin signaling. The findings highlight a novel mechanism linking metabolic modulation to neuroprotection, opening avenues for research into insulin signaling pathways in neurodegeneration.

• Ziprasidone Augmentation of Escitalopram in Anxious Depressi

  2026-05-20

  This study rigorously evaluated whether adding ziprasidone to escitalopram yields additional benefits for patients with anxious depression versus those without. The key finding is that ziprasidone augmentation did not confer clinically meaningful anxiolytic effects, underscoring the need for more targeted approaches in antidepressant research.

• Bestatin (Ubenimex): Precision Aminopeptidase Inhibition in

  2026-05-20

  Bestatin (Ubenimex) stands out as a highly specific aminopeptidase inhibitor, enabling reproducible assays in cancer and multidrug resistance research. Its unique solubility and selectivity profile unlock new experimental workflows, as evidenced by recent advances in angiogenesis modeling and apoptosis evaluation.

• Calpeptin: Mechanistic Insights and Strategic Impact in Fibr

  2026-05-19

  This article explores Calpeptin’s mechanistic role as a calpain inhibitor in modulating fibrosis and inflammation, synthesizing current evidence from translational models and recent studies on extracellular vesicle biology. It offers strategic guidance for researchers navigating complex disease modeling, protocol design, and the evolving competitive landscape, with a forward-looking perspective on translational opportunities and experimental rigor.

• Nonivamide (Capsaicin Analog): Translating TRPV1 Agonism to

  2026-05-19

  Discover how Nonivamide, a selective capsaicin analog, uniquely enables advanced TRPV1-driven studies in inflammation and cancer research. Explore mechanistic insights, translational assay guidance, and practical protocol parameters that set this article apart.

• M344: Next-Generation HDAC Inhibition in Neuroblastoma Resea

  2026-05-18

  Explore how M344, a potent histone deacetylase inhibitor, is reshaping neuroblastoma and pediatric cancer research through advanced epigenetic modulation. This article delivers a unique, evidence-driven perspective on assay design, clinical translation, and future directions.

• PINK1/Park2 Mitophagy Alleviates NAFLD: Mechanistic Insights

  2026-05-18

  The reference study provides new evidence that activation of PINK1/Park2-mediated mitophagy can relieve mitochondrial dysfunction and lipid accumulation in non-alcoholic fatty liver disease (NAFLD) models. These findings clarify the protective role of mitophagy in NAFLD pathology and highlight Park2 as a potential therapeutic target.

• Ginsenoside Rg1: Advanced Neuroprotection & Workflow Optimiz

  2026-05-17

  Ginsenoside Rg1, a triterpene saponin from Panax species, enables precise modulation of neuroimmune pathways for robust neuroprotection and inflammation studies. This guide details optimized experimental workflows, key protocol parameters, and troubleshooting strategies to maximize reproducibility and translational value using APExBIO’s high-purity Ginsenoside Rg1.

• (+)-Bicuculline: Technical Use as a GABAA Receptor Antagonis

  2026-05-16

  (+)-Bicuculline enables precise inhibition of GABAA receptors to dissect inhibitory synaptic transmission and modulate NMDA receptor signaling in neuroscience assays. It should only be used in controlled research environments with rigorous attention to solubility, storage, and workflow protocols. This compound is not suitable for diagnostic or clinical applications.

• LY2228820: Precision p38 MAP Kinase Inhibitor for Cellular A

  2026-05-15

  LY2228820 empowers researchers to dissect p38 MAPK signaling with unprecedented selectivity, supporting robust anti-inflammatory and cancer research. This guide delivers actionable workflows, protocol optimizations, and troubleshooting strategies to maximize reproducibility and scientific insight.

• EV-Transferred ACLY Drives Immunosuppressive Macrophage Diff

  2026-05-15

  This study uncovers how hepatocellular carcinoma (HCC) cells use extracellular vesicles to deliver ATP-citrate lyase (ACLY) into monocytes, inducing their differentiation into tumor-associated macrophages (TAMs) with potent immunosuppressive properties. These insights inform targeted strategies to modulate the tumor microenvironment and enhance immunotherapy in HCC.

• SOAT1 Inhibition Restores Lipophagy in PHMG-Induced Lung Fib

  2026-05-14

  This study identifies sterol O-acyltransferase 1 (SOAT1) as a key mediator of pulmonary fibrosis following polyhexamethylene guanidine (PHMG) exposure, linking SOAT1 upregulation to disrupted cholesterol handling and foam cell formation in alveolar macrophages. Targeting SOAT1 with avasimibe restored lipophagy and mitigated fibrosis, suggesting a promising therapeutic direction for PHMG-induced and possibly other lipid-driven fibrotic lung diseases.

15146 records 1/1010 page Next 12345 下5页 Last page